Article Text

PDF
Authors’ response
  1. J M H Van den Brande1,
  2. D W Hommes2,
  3. M P Peppelenbosch1
  1. 1
    Department of Cell Biology, University Medical Center Groningen, University of Groningen, The Netherlands
  2. 2
    Department of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands
  1. Dr M P Peppelenbosch, Department of Cell Biology, University Medical Center Groningen, University of Groningen, A Deusinglaan 1, 9713 AV Groningen, The Netherlands; M.P.Peppelenbosch{at}med.umcg.nl

Statistics from Altmetric.com

We have read with interest the correspondence from Derer et al regarding our paper. Our study showed that increases of mucosal apoptosis 24 h after an infusion of infliximab strongly correlate with the clinical success of infliximab (a chimeric antitumour necrosis factor (TNF) antibody and an anti-TNF medication) with respect to inducing remission in patients with moderate to severe Crohn’s disease. In their correspondence, Derer et al point out that certolizumab (a …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.